In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aurora Spine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TSXV:ASG - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	17	-1	-1	0	N/A
6/30/2024	16	-1	-1	0	N/A
3/31/2024	16	-1	-1	0	N/A
12/31/2023	15	-2	-1	-1	N/A
9/30/2023	14	-2	-1	0	N/A
6/30/2023	14	-2	-1	0	N/A
3/31/2023	14	-2	-1	-1	N/A
12/31/2022	15	-2	-2	-2	N/A
9/30/2022	14	-2	-3	-1	N/A
6/30/2022	13	-2	-4	-3	N/A
3/31/2022	12	-2	-4	-3	N/A
12/31/2021	11	-2	-3	-2	N/A
9/30/2021	10	-1	-3	-2	N/A
6/30/2021	9	-1	-1	-1	N/A
3/31/2021	9	0	0	0	N/A
12/31/2020	9	0	0	0	N/A
9/30/2020	9	-1	0	1	N/A
6/30/2020	9	-2	0	0	N/A
3/31/2020	11	-2	-1	0	N/A
12/31/2019	11	-1	0	0	N/A
9/30/2019	11	-1	0	0	N/A
6/30/2019	11	0	0	0	N/A
3/31/2019	10	0	0	1	N/A
12/31/2018	9	0	0	0	N/A
9/30/2018	8	-1	0	0	N/A
6/30/2018	7	-1	N/A	-1	N/A
3/31/2018	6	-2	N/A	-1	N/A
12/31/2017	6	-2	N/A	-1	N/A
9/30/2017	6	-2	N/A	-1	N/A
6/30/2017	6	-2	N/A	-1	N/A
3/31/2017	7	-2	N/A	-2	N/A
12/31/2016	7	-2	N/A	-2	N/A
9/30/2016	7	-2	N/A	-2	N/A
6/30/2016	6	-2	N/A	-2	N/A
3/31/2016	5	-2	N/A	-2	N/A
12/31/2015	5	-3	N/A	-3	N/A
9/30/2015	5	-5	N/A	-4	N/A
6/30/2015	4	-6	N/A	-6	N/A
3/31/2015	4	-8	N/A	-7	N/A
12/31/2014	3	-8	N/A	-7	N/A
9/30/2014	1	-6	N/A	-7	N/A
6/30/2014	1	-5	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ASG's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if ASG's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if ASG's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ASG's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if ASG's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ASG's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/01 01:39
End of Day Share Price	2025/05/01 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aurora Spine Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Neal Gilmer	Clarus Securities Inc.

Aurora Spine Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Recent updates

Aurora Spine Corporation to Report Q4, 2024 Results on Apr 28, 2025

Aurora Spine Corporation, Annual General Meeting, Jun 16, 2025

Aurora Spine Corporation Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™? Sacroiliac Joint Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for the Aero™? Facet Fusion System

Aurora Spine Corporation Announces Completion of Enrollment in Groundbreaking REFINE Study

Slammed 30% Aurora Spine Corporation (CVE:ASG) Screens Well Here But There Might Be A Catch

Aurora Spine Corporation Announces the Promotion of Matt Paxton to Executive Vice President of Sales

Third quarter 2024 earnings released

Aurora Spine Corporation (CVE:ASG) Soars 26% But It's A Story Of Risk Vs Reward

We Think Aurora Spine (CVE:ASG) Has A Fair Chunk Of Debt

Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar System

Second quarter 2024 earnings released: US$0.023 loss per share (vs US$0.007 loss in 2Q 2023)

Aurora Spine Corporation's (CVE:ASG) Subdued P/S Might Signal An Opportunity

We Think Shareholders May Want To Consider A Review Of Aurora Spine Corporation's (CVE:ASG) CEO Compensation Package

Is Aurora Spine (CVE:ASG) A Risky Investment?

Full year 2023 earnings released: US$0.02 loss per share (vs US$0.022 loss in FY 2022)

Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024

Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024

New minor risk - Insider selling

Independent Director recently sold CA$135k worth of stock

There Is A Reason Aurora Spine Corporation's (CVE:ASG) Price Is Undemanding

New minor risk - Share price stability

Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual Meeting

Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion Implant

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.002 loss in 3Q 2022)

Independent Director recently bought CA$105k worth of stock

Aurora Spine Corporation announced that it has received CAD 1.933782 million in funding

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation System

Second quarter 2023 earnings released: US$0.01 loss per share (vs US$0.002 loss in 2Q 2022)

Why Investors Shouldn't Be Surprised By Aurora Spine Corporation's (CVE:ASG) Low P/S

Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter Study

Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023

Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023

Here's Why Aurora Spine (CVE:ASG) Can Afford Some Debt

Full year 2022 earnings released: US$0.02 loss per share (vs US$0.04 loss in FY 2021)

Independent Chairman exercised options to buy CA$355k worth of stock.

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

Third quarter 2022 earnings released: US$0.002 loss per share (vs US$0.007 loss in 3Q 2021)

Aurora Spine Corporation to Report Q3, 2022 Results on Nov 21, 2022

Insufficient new directors

Aurora Spine Corporation Announces Positive Interim Results from Clinical Study Using Zip(TM) MIS Interspinous Fusion System

Aurora Spine Corporation Announces FDA 510(K) Clearance for Its Silo TFX MIS Sacroiliac Joint Fixation System

Second quarter 2022 earnings released: US$0.002 loss per share (vs US$0.013 loss in 2Q 2021)

Aurora Spine Corporation to Report Q2, 2022 Results on Aug 29, 2022

Would Aurora Spine (CVE:ASG) Be Better Off With Less Debt?

Aurora Spine Announces New FDA Indication Clearance of Lumbar Spinal Stenosis for Its ZIP™ Series of MIS Implants

Aurora Spine Corporation Receives FDA 510(K) Clearance for Its Dexa Solo-LTM Spinal Fusion System

Aurora Spine Corporation to Report Q1, 2022 Results on May 23, 2022

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Full year 2021 earnings released: US$0.04 loss per share (vs US$0.004 loss in FY 2020)

Insufficient new directors

Aurora Spine Corporation Announces Initial Implantation of the First Bone Density Matched DEXA-C Cervical Interbody Fusion Device

Aurora Spine Corporation Provides Revenue Guidance for Fourth Quarter and Full Year 2021

Aurora Spine Corporation Receives Notice of Allowance for Patent for Spinal Implant for Motion Preservation or Fusion

Aurora Spine Corporation Completes First Anterior Cervical Discectomy and Fusion Procedures with its Proprietary APOLLOTM Anterior Cervical Plate

Health Check: How Prudently Does Aurora Spine (CVE:ASG) Use Debt?

Aurora Spine Corporation Announces Newly Published Paper on Need for A Bone Mineral Density-Matched Interbody Cage

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.006 profit in 3Q 2020)

Aurora Spine Corporation Will Showcase Its New FDA-Cleared DEXA-C Anterior Fusion Cages At the North American Spine Society Annual Meeting

Aurora Spine Corporation announced that it has received CAD 6.508139 million in funding

Second quarter 2021 earnings released: US$0.01 loss per share (vs US$0.001 profit in 2Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Announces First Patients in Multicenter Study of ZIP® Interspinous Fixation Device

Aurora Spine Corporation Announces FDA 510(K) Clearance for DEXA-C Cervical Interbody System

Aurora Spine (CVE:ASG) Is Making Moderate Use Of Debt

First quarter 2021 earnings released: US$0.01 loss per share (vs US$0.011 loss in 1Q 2020)

Aurora Spine Corporation Provides Revenue Guidance for the Year 2021

Aurora Spine Corporation Receives Irb Approval to Commence Registration for Multicenter Study of Its Silo™ Device for Si Joint Pain

Full year 2020 earnings released

Aurora Spine Corporation Announces Launch of its SiLOTM Posterior SI Joint Fusion System

A Look At The Intrinsic Value Of Aurora Spine Corporation (CVE:ASG)